MicroRNA-543-3p a potential chemotherapy marker regulates the messenger RNA expression of survivin in patients with advanced breast cancer

Authors

  • Saleh Ali Alghamdi Associate Professor of Medical Genetics, Clinical Laboratory Department, College of Applied Medical Sciences, Taif University
  • Ayman Alhazmi Associate Professor of Clinical Biochemistry and Molecular Biology, Clinical Laboratory Department, College of Applied Medical Sciences, Taif University
  • Ashjan Shami Assistant professor of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University
  • Amal F. Gharib Professor of Medical Biochemistry and Molecular Biology, Clinical Laboratory Department, College of Applied Medical Sciences, Taif University, SA. and Professor of Medical Biochemistry and Molecular Biology, Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Zagazig University Egypt
  • Wael Hassan Elsawy Professor of Clinical Oncology, Clinical Oncology Department, Faculty of Medicine, Zagazig University, Egypt.
  • Majed Al Mourgi Department of Surgery, College of Medicine, Taif University, Taif.

Keywords:

LABC, miRNA-542-3p, NAC, real-time quantitative polymerase chain reaction, survivin mRNA

Abstract

Objectives: Induction chemotherapy (ICT) is the standard of care for patients with locally advanced breast cancer. The major criticism about ICT is the delay of surgery, which may affect the local control. Survivin functions by the regulation of mitosis and inhibition of apoptosis. The miR-542-3p regulates survivin mRNA, upregulation of miR-542-3p leads to the downregulation of survivin and arrest of the cell cycle at G1 and G2/M phases resulting in tumor growth suppression. We studied whether we can use survivin mRNA and miRNA-542-3p as potential biomarkers to predict response to ICT.

Methods: Fifty-one patients with locally advanced breast cancer were treated with ICT. miRNA-542-3p and survivin mRNA were determined in breast cancerous tissues and their nearby healthy breast tissues by a real-time quantitative polymerase chain reaction.

Results: Our results revealed a negative correlation between miRNA and survivin. miRNA-542-3p levels were elevated in normal tissues and in patients with good prognostic features and response to ICT. On the contrary, survivin was upregulated in malignant tissues in patients with adverse prognostic features and patients with no
response to neoadjuvant chemotherapy.

Conclusions: ICT is a promising option for the treatment of patients with locally advanced carcinoma of the breast. The studied miRNA-542-3p and its target survivin correlate inversely with each other in both malignant and their nearby normal tissues. miRNA-542-3p and survivin can be used as possible molecular markers for the
prediction of response to ICT in locally advanced carcinoma of the breast.

Downloads

Published

2020-06-29

How to Cite

Alghamdi, S. A. ., Alhazmi , A. ., Shami , A. ., Gharib, A. F., Elsawy, W. H., & Al Mourgi, M. (2020). MicroRNA-543-3p a potential chemotherapy marker regulates the messenger RNA expression of survivin in patients with advanced breast cancer. International Journal of Health Sciences, 14(4), 29–37. Retrieved from https://pub.qu.edu.sa/index.php/journal/article/view/5001

Issue

Vol. 14 No. 4 (2020): Jul-Aug

Section

Original Paper

License


Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Most read articles by the same author(s)